Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

Mishima, K

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. [electronic resource] - Cancer research Jul 2001 - 5349-54 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0008-5472


Animals
Antibodies, Monoclonal--pharmacology
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Blotting, Western
Brain Neoplasms--drug therapy
Cell Division--drug effects
Down-Regulation--drug effects
ErbB Receptors--genetics
Gene Expression Regulation, Neoplastic
Glioblastoma--drug therapy
Humans
In Situ Nick-End Labeling
Mice
Mice, Nude
Mutation
Neovascularization, Pathologic--prevention & control
Phosphorylation--drug effects
Proto-Oncogene Proteins c-bcl-2--drug effects
Survival Analysis
Survival Rate
Transplantation, Heterologous
Treatment Outcome
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
bcl-X Protein